In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

The Art of CCIT: Deterministic Method Selection
Webinars, Pharmaceutical, Market Insights, Product Solutions

Vial Stopper Compatibility: Criteria and Testing Methods
Publications, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions

Derisking the Development of Sensitive Injectables
Webinars, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions

Helping Pharma Manufacturers Meet New Annex 1 Requirements
Publications, Pharmaceutical, Market Insights, Product Solutions